Background：Intercellular crosstalk among osteoblast, osteoclast, osteocyte and
chondrocyte is involved in the precise control of bone homeostasis. Disruption of this cellular
and molecular signaling would lead to metabolic bone diseases such as osteoporosis.
Currently a number of anti-osteoporosis interventions are restricted by side effects, complications
and long-term intolerance. This review aims to summarize the bone cellular communication
involved in bone remodeling and its usage to develop new drugs for osteoporosis.
Methods：We searched PubMed for publications from 1 January 1980 to 1 January 2018 to
identify relevant and latest literatures, evaluation and prospect of osteoporosis medication
were summarized. Detailed search terms were ‘osteoporosis’, ‘osteocyte’, ‘osteoblast’, ‘osteoclast’,
‘bone remodeling’, ‘chondrocyte’, ‘osteoporosis treatment’, ‘osteoporosis therapy’,
‘bisphosphonates’, ‘denosumab’, ‘Selective Estrogen Receptor Modulator (SERM)’, ‘PTH’,
‘romosozumab’, ‘dkk-1 antagonist’, ‘strontium ranelate’.
Results：A total of 170 papers were included in the review. About 80 papers described bone
cell interactions involved in bone remodeling. The remaining papers were focused on the
novel advanced and new horizons in osteoporosis therapies.
Conclusion：There exists a complex signal network among bone cells involved in bone remodeling.
The disorder of cell-cell communications may be the underlying mechanism of osteoporosis.
Current anti-osteoporosis therapies are effective but accompanied by certain
drawbacks simultaneously. Restoring the abnormal signal network and individualized therapy
are critical for ideal drug development.